Curis (CRIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Oct, 2026Executive summary
Special meeting set for Nov. 18, 2026, online; stockholders will vote on a 1-for-5 to 1-for-12 reverse split and possible adjournment.
Record date is Oct. 26, 2026; the board intends to implement the split if approved, subject to its discretion and authority to abandon it.
Voting matters and shareholder proposals
The board recommends FOR both proposals; each requires a majority of votes cast, and abstentions have no effect.
Adjournment would allow additional proxy solicitation if votes for the reverse split are insufficient, including postponing a vote to seek support.
Proposals for inclusion in the 2027 annual-meeting proxy are due by Dec. 22, 2026; other proposals and nominations generally require notice Jan. 19–Feb. 18, 2027.
Board of directors and corporate governance
If approved, the board may set the split ratio and timing and file the amendment within six months; it may abandon the split before filing or effectiveness.
The selected ratio will be publicly announced before effectiveness; approval covers each whole-number ratio from 1-for-5 through 1-for-12.
Latest events from Curis
- Net loss increased, cash runway is short, and additional funding is urgently needed to sustain operations.CRIS
Q2 2026 - Best-efforts offering seeks up to $13.6M for R&D, but going concern risk and dilution remain high.CRIS
Registration filing - Emavusertib delivers superior efficacy and safety in hematologic cancers, advancing toward approval.CRIS
Corporate presentation - Emavusertib plus BTKi achieves strong PCNSL responses and advances, pending further funding.CRIS
Study update - Reverse stock split and adjournment proposals were both approved by majority vote.CRIS
EGM 2026 - Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation - Q3 net loss narrowed, emavusertib data positive, but funding needed beyond mid-2025.CRIS
Q3 2024 - Emavusertib gains EU ODD as Q2 net loss hits $11.8M and cash runway extends into Q1 2025.CRIS
Q2 2024 - Emavusertib advances on accelerated approval path with strong data, improved financials, and funding risks.CRIS
Q4 2024